Tenofovir, lamivudine and efavirenz — Competitive Intelligence Brief

Tenofovir, lamivudine and efavirenz (Tenofovir, lamivudine and efavirenz) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NRTI/NtRTI + NNRTI). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (NRTI/NtRTI + NNRTI) HIV reverse transcriptase, HIV integrase Infectious Disease / Virology Small molecule

Target snapshot

Tenofovir, lamivudine and efavirenz (Tenofovir, lamivudine and efavirenz) — Centre for the AIDS Programme of Research in South Africa. This fixed-dose combination of three antiretroviral drugs inhibits HIV reverse transcriptase and integrase to suppress viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tenofovir, lamivudine and efavirenz TARGET	Tenofovir, lamivudine and efavirenz	Centre for the AIDS Programme of Research in South Africa	marketed	Antiretroviral combination therapy (NRTI/NtRTI + NNRTI)	HIV reverse transcriptase, HIV integrase
TDF/3TC/EFV or DTG or NVP	TDF/3TC/EFV or DTG or NVP	MU-JHU CARE	marketed	Antiretroviral combination therapy (NRTI + NNRTI or INSTI)	HIV reverse transcriptase, HIV integrase
Switch to Triumeq	Switch to Triumeq	McGill University Health Centre/Research Institute of the McGill University Health Centre	marketed	Antiretroviral combination therapy (NRTI + INSTI)	HIV reverse transcriptase, HIV integrase
Antiretroviral therapy	Antiretroviral therapy	ANRS, Emerging Infectious Diseases	marketed	Combination antiretroviral therapy (multiple classes: nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors, entry inhibitors)	HIV reverse transcriptase, HIV integrase, HIV protease, HIV envelope glycoproteins (gp120/gp41), CCR5 co-receptor
DOR/DTG/3TC	DOR/DTG/3TC	Insel Gruppe AG, University Hospital Bern	marketed	Antiretroviral combination (NNRTI + INSTI + NRTI)	HIV reverse transcriptase, HIV integrase
Atripla (r)	Atripla (r)	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Antiretroviral combination (NNRTI + NRTI + NtRTI)	HIV reverse transcriptase, HIV integrase
tenofovir, lamivudine, efavirenz	tenofovir, lamivudine, efavirenz	Bamrasnaradura Infectious Diseases Institute	marketed	Antiretroviral combination therapy (NRTI/NtRTI/NNRTI)	HIV reverse transcriptase, HIV integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NRTI/NtRTI + NNRTI) class)

1. Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 drug in this class
2. Centre for the AIDS Programme of Research in South Africa · 1 drug in this class